1-烯丙基-3-甲基-1H-吡唑-5-羧酸 | 319474-61-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-烯丙基-3-甲基-1H-吡唑-5-羧酸
• 英文名称: 2-allyl-5-methyl-2H-pyrazole-3-carboxylic acid
• 英文别名: 2-Allyl-5-methyl-2H-pyrazol-3-carbonsaeure；1-allyl-3-methyl-1H-pyrazole-5-carboxylic acid；5-methyl-2-prop-2-enylpyrazole-3-carboxylic acid
• CAS: 319474-61-8
• 化学式: C₈H₁₀N₂O₂
• 分子量: 166.18
• InChiKey: HLMMLSCUQFNMDV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-烯丙基-3-甲基-1H-吡唑-5-羧酸 在 氯化亚砜 作用下， 生成 2-allyl-5-methyl-2H-pyrazole-3-carbonyl chloride
  参考文献：
  名称：

  Über Pyrazol-karbonsäure-amide

  摘要：

  DOI：

  10.1002/ardp.19432810403

文献信息

• [EN] INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE<br/>[FR] COMPOSES D'INDAZOLE ET COMPOSITIONS PHARMACEUTIQUES INHIBANT LES PROTEINES KINASES, ET PROCEDES D'UTILISATION DE CEUX-CI
  申请人：AGOURON PHARMA

  公开号：WO2001002369A2

  公开（公告）日：2001-01-11

  Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

  本文描述了调节和/或抑制某些蛋白激酶活性的吲唑化合物。这些化合物和含有它们的药物组合物能够介导酪氨酸激酶信号转导，从而调节和/或抑制不需要的细胞增殖。本发明还涉及含有这些化合物的药物组合物的治疗或预防用途，并通过给予有效量的这些化合物的方法治疗癌症和其他与不需要的血管生成和/或细胞增殖有关的疾病状态，例如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和牛皮癣。
• INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE
  申请人：——

  公开号：US20040220248A1

  公开（公告）日：2004-11-04

  Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

  本文介绍了调节和/或抑制某些蛋白激酶活性的吲唑类化合物。这些化合物及含有它们的药物组合物能够介导酪氨酸激酶信号转导，从而调节和/或抑制不必要的细胞增殖。本发明还涉及含有这些化合物的药物组合物的治疗或预防用途，以及通过给予有效量的这些化合物来治疗癌症和其他与不必要的血管生成和/或细胞增殖相关的疾病状态，如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和牛皮癣的方法。
• [EN] HETEROCYCLIC AMIDE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF<br/>[FR] COMPOSÉ AMIDE HÉTÉROCYCLIQUE, SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, ET SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION<br/>[ZH] 杂环酰胺类化合物、其可药用的盐及其制备方法和用途
  申请人：SHANGHAI INST MATERIA MEDICA CAS

  公开号：WO2021052501A1

  公开（公告）日：2021-03-25

  一种通式(I)的杂环酰胺类化合物、其可药用盐及其制备方法，以及所述化合物在制备治疗与STING活性相关的疾病的药物中的用途、在制备免疫佐剂中的用途、在制备激活STING药物中的用途。
• Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
  申请人：AGOURON PHARMACEUTICALS, INC.

  公开号：EP1614683B1

  公开（公告）日：2007-11-21
• HETEROCYCLIC AMIDE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF
  申请人：Shanghai Institute of Materia Medica, Chinese Academy of Sciences

  公开号：US20220389025A1

  公开（公告）日：2022-12-08

  Provided are a heterocyclic amide compound of general formula (I), a pharmaceutically acceptable salt thereof and a preparation method therefor, and the use of the compound in the preparation of a drug for treating diseases related to the activity of STING, in the preparation of an immunologic adjuvant, and in the preparation of a drug for activating STING.